Apple — THERMOMETER

"THERMEX-16" — 16 channels thermometer interface to Apple II* computers.

FOR: PYROGENIC ACTIVITY, INFLAMMATION
HYPOTHERMAL ONCOLOGY
AND BLOOD CIRCULATION MAPPING

- Accuracy ± 1/10°C at 22°C ambient
- Resolution 1/10°C
- Range 0°C to 50°C for biological applications (other ranges available on request)
- Displays, prints and stores results on the disc from all 16 channels
- Variety of rectal, intravenous, hypodermic and implantable probes available
- Optional program for plotting temp. curves versus time available

COLUMBUS INSTRUMENTS INTERNATIONAL CORPORATION

950 N. HAGUE AVE., COLUMBUS, OHIO 43204 U.S.A.
PHONE: (614) 488-6176  TELEX: 246514
THE BLUNT TRUTH
FOR CONTINUOUS DOSING, CONVENIENCE, AND RESULTS...
ALZET® OSMOTIC PUMPS DELIVER:

CONTINUOUS DOSING

Alzet Osmotic Pumps offer the choice of 1-4 weeks of delivery, night and day, for continuous presence of even the shortest half-life agent.

RESULTS

Multiday infusions insure that you measure the fully-developed actions of your test agent in the steady-state. Single-dose studies are useful, but the actions of many agents are far from fully developed by a single dose. The Alzet Osmotic Pumps have demonstrated their ability to deliver good results in nearly a thousand publications.

NEW APPLICATIONS

Alzet Osmotic Pumps are now being used for direct tissue microperfusion with labelled amino acids and other precursors to demonstrate in vivo biosynthesis. Another new application of the pumps is localized drug delivery to the rat kidney via renal arterial infusion.

To place an order, call toll-free 800-227-9953. In California, Alaska & Hawaii call collect (415) 494-5067. For more information mail the coupon below.

OSMOTIC PUMPS
Please send me information on the Alzet Osmotic Pumps.

CR-1-85

Name:
Affiliation:
Address:
City_ State__ Zip
Mail to: ALZA Corporation
Dept. Y, P.O. Box 10950
950 Page Mill Rd.
Palo Alto, CA 94303-0802

CONVENIENCE

Implantation can be completed in less than one minute. It is easily mastered. ALZA Corporation loans free of charge a videocassette showing subcutaneous and other implantation procedures.
International Agency for Research on Cancer Scientific Publications

Oxford University Press is pleased to announce that we are now distributing this series worldwide (previously distributed by the World Health Organization, which will continue to distribute the IARC Monographs on the Evaluation of the Carcinogenic Risk to Humans).

New Titles

53. **Nickel in the Human Environment**
Editor-in-Chief F.W. Sunderman, Jr.
0 19 723059 8 500 pp. illustrated £30/$52.50

56. **Models, Mechanisms and Etiology of Tumour Promotion**
Edited by M. Bőrzsönyi et al
0 19 723058 X 500 pp. £22.50/$40

57. **N-Nitroso Compounds: Occurrence, Biological Effects and Relevance to Human Cancer**
Edited by I.K. O'Neill et al
0 19 723055 5 1200 pp. £40/$70

59. **Monitoring Human Exposure to Carcinogenic and Mutagenic Agents**
Edited by A. Berlin et al
0 19 723056 3 450 pp. £20/$35

60. **Burkitt's Lymphoma: A Human Cancer Model**
Edited by G. Lenoir et al
0 19 723057 1 450 pp. £20/$35

61. **Laboratory Decontamination and Destruction of Carcinogens in Laboratory Wastes: Some Haloethers**
Edited by M. Castegnaro et al
0 19 723061 X 55 pp. £6.95/$11.95 paperback

62. **Directory of On-going Research in Cancer Epidemiology 1984**
Edited by C. Muir and G. Wagner
0 19 723062 8 700 pp. £18/$26.50 paperback

Oxford University Press

Help us to serve you better.....

If your mailing label does not contain your zip code, note it on the label and return it to us for correction.

Remember, your Zip Code provides faster, more direct delivery of your journals. Use it on all correspondence, too.
The Division of Cancer Etiology

National Cancer Institute
Announces To The Scientific Community The Availability Of The Following Resources/Services For Cancer Related Research As Noted Below:

<table>
<thead>
<tr>
<th>Biological Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Avian Myeloblastosis Virus Reverse Transcriptase</strong>—2,000 Unit Minimum Order</td>
</tr>
</tbody>
</table>
| **Contact**: Life Sciences, Inc.  
2900 72nd Street North  
St. Petersburg, FL 33710  
(813) 346-9371  
Citing Contract #N01-CP-11013 |
| **Cost**: $0.07/Unit Plus Shipping |

| **Viruses**: Avian, Feline, Murine, and Primate Viruses Prepared in Tissue Culture |
| **Contact**: Coordinator for Research Resources  
Biological Carcinogenesis Branch, DCE, NCI, NIH  
Landow Bldg., Room 9A22  
Bethesda, MD 20205  
(301) 496-1951 |
| **Cost**: Inquire |

| Human Tissues: Carcinomas, Sarcomas, Melanomas, Lymphomas, Leukemias, Benign Tumors and other Non-Malignant Disorders |
| **Contact**: Coordinator for Research Resources  
Biological Carcinogenesis Branch, DCE, NCI, NIH  
Landow Bldg., Room 9A22  
Bethesda, MD 20205  
(301) 496-1951 |
| **Cost**: Shipping Charges Only |

| Baboon Sera Collected from Animals in Sukhumi, USSR with High and Low Incidence of Malignant Lymphoma |
| **Contact**: Coordinator for Research Resources  
Biological Carcinogenesis Branch, DCE, NCI, NIH  
Landow Bldg., Room 9A22  
Bethesda, MD 20205  
(301) 496-1951 |
| **Cost**: Shipping Charges Only |

| **Tissues**: Avian, Bovine, Feline, and Primate Intact Viruses and Viral Proteins; Antibodies to Immunoglobulins for a number of species. Preimmune Sera available for some Virus Antisera |
| **Contact**: Coordinator for Research Resources  
Biological Carcinogenesis Branch, DCE, NCI, NIH  
Landow Bldg., Room 9A22  
Bethesda, MD 20205  
(301) 496-1951 |
| **Cost**: $10.00/Unit Plus Shipping (Preimmune Sera—$5.00/Unit) |

| **Sera** from Primates which were housed in the U.S. and inoculated with Material from the Sukhumi Baboons |
| **Contact**: Coordinator for Research Resources  
Biological Carcinogenesis Branch, DCE, NCI, NIH  
Landow Bldg., Room 9A22  
Bethesda, MD 20205  
(301) 496-1951 |
| **Cost**: Shipping Charges Only |

<table>
<thead>
<tr>
<th><strong>Chemical Resources</strong></th>
</tr>
</thead>
</table>

| **Chemical Carcinogen Reference Standard Repository**: Reference Quantities of nearly 700 compounds are available. Included are numerous representatives of the following classes: poly- |  |
| nuclear aromatic hydrocarbons, PAH metabolites, radiolabeled PAH metabolites, nitrogen heterocycles, nitrosonium/nitrosamides, aromatic amines, aromatic amine metabolites, |  |
| radiolabeled retinoids, azo/azoxy aromatics, inorganics, nitroaromatics, pesticides, pharmaceuticals, natural products, dyes, dioxins, chlorinated aliphatics and miscellaneous groups. Data |  |
| sheets provided with the compounds, include chemical and physical properties, analytical data, |  |
| hazards, storage, and handling information. Catalog available upon request |
| **Contact**: Coordinator for Chemical Research Resources  
Chemical and Physical Carcinogenesis Branch, DCE, NCI  
Landow Bldg/Rm 9801  
Bethesda, MD 20205  
(301) 496-5471 |
| **Cost**: Subject to chemical class code and quantity (see catalog) |

| **Epidemiology Resources** |

| The Immunodeficiency—Cancer Registry (ICR) is a unique registry of cancer cases that occur in patients with naturally-occurring immunodeficiencies. Case material collected by the ICR comes from case reports appearing in scientific literature and voluntary reporting by physicians. Criteria for inclusion in the registry are clinical or laboratory evidence of a primary immunodeficiency syndrome prior to the onset of malignancy. Data contained in the ICR are available to the extramural research community for the planning, design, and conduct of research efforts. Limited assistance is available to investigators interested in utilizing the registry |
| **Contact**: Dr. Alexandra H. Filipovich  
Immunodeficiency—Cancer Registry  
Box 610 Mayo  
University of Minnesota  
Minneapolis, MN 55455  
(612) 376-2174  
Citing Contract #N01-CP3-1011 |

| **Sera** from Patients who were obtained from nonhuman primates inoculated with EBV |
| **Contact**: Dr. Paul H. Levine  
Cancer Epidemiology Branch, DCE, NCI, NIH  
Landow Building, Room 8C41  
Bethesda, MD 20205  
(301) 496-5067 |
| **Cost**: Free to Collaborating Investigators; Others—Shipping Charges Only |

The Tumor Virus Epidemiology Repository (TVER), contains sera and other biological samples from more than 13,000 patients and controls obtained in 12 different countries. The TVER was established primarily to support collaborative research on the role of Epstein-Barr virus (EBV) in Burkitt's lymphoma, nasopharyngeal carcinoma, and related diseases. Part of the collection includes sera that were obtained from nonhuman primates inoculated with EBV. The TVER is able to adjust its collection to facilitate the development of new collaborative studies. In addition, some samples are available for reagents and independent research. The most extensive collections are serum samples from patients with Burkitt's lymphoma (sera from more than 1000 patients) |
---

**Contact**: Dr. Paul H. Levine  
Cancer Epidemiology Branch, DCE, NCI, NIH  
Landow Building, Room 8C41  
Bethesda, MD 20205  
(301) 496-5067  
Citing Contract #N01-CP3-1011  
**Cost**: Free to Collaborating Investigators; Others—Shipping Charges Only

---

**Contact**: Coordinator for Research Resources  
Biological Carcinogenesis Branch, DCE, NCI, NIH  
Landow Bldg., Room 9A22  
Bethesda, MD 20205  
(301) 496-1951  
Citing Contract #N01-CP2-2004  
**Cost**: $10.00 per diem (or higher for procedures involving additional care, etc.) $10.00 per blood sample
COVER LEGEND

The Ludwig Institute for Cancer Research began as a medical research organization in 1971, through the benefaction of Daniel K. Ludwig, in Zurich, Switzerland. The purpose of the Institute is to originate and conduct, by a full-time research staff in its own facilities, incisive long-range research programs in cancer in conjunction with hospitals in established medical centers. It is precluded by its charter from making research grants or endowments.

The main component of the Institute’s organization is the Ludwig branch, in Zurich. However, nine others already are in operation: London, England (established 1971; Director, A. M. Neville), Lausanne, Switzerland (established 1973; Director, J-C. Cerrotini), Sydney, Australia (established 1976; Director, M. H. Tattersall), Brussels, Belgium (established 1978; Director, T. Boon), Bern, Switzerland (established 1979; Director, B. Groner), Melbourne, Australia (established 1980; Director, T. Burgess), Cambridge, England (established 1981; Director, K. Sikora), Toronto, Ontario, Canada (established 1981; Director, R. Bruce), and São Paulo, Brazil (established 1983; Director, R. Brentani). More branches are to be established in the future. Each will constitute a strategically placed research center functioning as an arm of the Institute’s comprehensive strategy against cancer. The worldwide staff currently totals 350, 140 of whom have doctoral degrees.

All branches are developed within the academic and societal framework of the country where they are located. Prominent scientists in that region are involved in the selection of the branch’s Director and its research program. Every 3 years, each branch’s program is reviewed by an external review process. Further, each branch is served by a standing committee drawn from both professional and lay sectors of the community to assist in scientific development and matters of policy.

The Institute has a major interest in the study of: (1) breast cancer and colon cancer with emphasis on cellular and molecular biology (Bern, London, São Paulo); epidemiology (São Paulo, Toronto); diagnosis, prevention, and therapy (Bern, Lausanne, London, Sydney, Toronto); and (2) hematopoietic cancers with definition of growth factors involved in normal and abnormal proliferation (Melbourne); and the role of oncogenes (Cambridge, Melbourne). Another focus of the Institute’s program involves the application of immunological approaches to the study and control of cancer. These include: (1) analysis of the development, structure, and function of the cellular immune system (Lausanne); (2) generation and analysis of mouse and human monoclonal antibodies to cell surface antigens of human cancers and their use in imaging and therapy (Lausanne, London, Cambridge); and (3) development of a new approach to the therapy of cancer with antigenic tumor cell variants obtained by mutagenesis (Brussels).

Pictured are Mr. Daniel K. Ludwig (upper left) and members of the Scientific Advisory Committee (left to right): Hugh R. Butt, Chairman; Lloyd J. Old, Scientific Director; Elwood V. Jensen, Medical Director; Carl G. Baker, former Medical Director; and Henri Isliker. The map shows the locations of the ten branches of the Institute.